Guardant Health reports Q2 EPS (67c), consensus ($1.18)

Reports Q2 revenue $137.2M, consensus $129.4M. “We had another very strong quarter with revenue growing 26% year over year, driven by strength across precision oncology where we reached 50,000 combined tests during the quarter,” said Helmy Eltoukhy, co-founder and co-CEO. “Our clinical volumes were driven by growth in lung and breast cancer for Guardant360 and by rapid year-over-year growth for Reveal and TissueNext. With this strong momentum, we are on track to achieve cash flow breakeven in Therapy Selection within the next 3-6 months.” “We are continuing to make advancements in our screening business as we spearhead a new patient-preferred category with our Shield blood test,” said AmirAli Talasaz, co-founder and co-CEO. “In the near-term, we remain focused on obtaining FDA approval for the Shield test in colorectal cancer, preparing for the commercial launch of Shield IVD in 2024 and delivering on our plans to develop Shield into a multi-cancer test.”